Company profile of Sino-American Shanghai Squibb Pharmaceutical Co., Ltd.

Sino-American Shanghai Squibb Pharmaceutical Co., Ltd., which is jointly invested by Bristol-Myers Squibb Company, China Pharmaceutical Foreign Trade Corporation and Shanghai Pharmaceutical (Group) Corporation, is the first Sino-American joint venture pharmaceutical enterprise established in China. The registered capital of the company is US$ 11.64 million, with a total investment of US$ 29.48 million, and the ratio of Chinese and foreign investment is 4: 6. After continuous expansion and upgrading, the total investment has reached 6 million US dollars so far.

The company is located in Minhang High-tech Park in Shanghai, covering an area of about 53, square meters and a building area of about 36, square meters. Since its establishment, the company has been designing, producing, managing and operating in strict accordance with GMP standards. By the end of 12 years, the company had a cephalosporin production workshop and a non-cephalosporin production workshop. It can simultaneously produce oral tablets, capsules, solutions, dry suspensions, sterile powder injections and other different dosage forms, and 36 different dosage forms of drugs in 28 varieties in 5 categories. The company's quality assurance and control system takes the pursuit of "" defects as the goal, and strictly grasps the whole process from raw materials entering the factory to qualified products issuing and leaving the factory, so as to achieve "one stitch at a time, no loss". All products and production lines of the company have passed the national GMP certification.